Home » Stocks » ASLN

ASLAN Pharmaceuticals Limited (ASLN)

Stock Price: $2.45 USD -0.05 (-2.00%)
Updated Jan 27, 2021 1:47 PM EST - Market open
Market Cap 94.98M
Revenue (ttm) 3.00M
Net Income (ttm) -47.07M
Shares Out 160.25M
EPS (ttm) -1.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $2.45
Previous Close $2.50
Change ($) -0.05
Change (%) -2.00%
Day's Open 2.46
Day's Range 2.30 - 2.60
Day's Volume 633,066
52-Week Range 0.93 - 2.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors

GlobeNewsWire - 2 weeks ago

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels

Zacks Investment Research - 1 month ago

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 2 months ago

SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform th...

Zacks Investment Research - 2 months ago

ASLAN Pharmaceuticals (ASLN) has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 2 months ago

SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform th...

GlobeNewsWire - 3 months ago

--   ASLAN has initiated recruitment of patients into third dos e cohort at sites in the US, Australia and Singapore following successful safety review of second cohort

Zacks Investment Research - 3 months ago

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Seeking Alpha - 3 months ago

HitGen will acquire Vernalis Limited, a Cambridge, UK CRO, from Ligand Pharmaceuticals for $25 million.

Other stocks mentioned: LGND, LLY, PPD
GlobeNewsWire - 3 months ago

--  ASLAN believe s ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease , more than 30 times more potent at inhibiting the ...

GlobeNewsWire - 4 months ago

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments...

GlobeNewsWire - 4 months ago

SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments...

GlobeNewsWire - 5 months ago

Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020 Interim, unblinded data from all 3 dose cohorts in MAD study expected in 4Q 2020

GlobeNewsWire - 5 months ago

SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative ...

GlobeNewsWire - 5 months ago

SINGAPORE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...

GlobeNewsWire - 6 months ago

SINGAPORE, July 17, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...

Zacks Investment Research - 6 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 6 months ago

SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative ...

Zacks Investment Research - 7 months ago

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Zacks Investment Research - 7 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $1.92 in the latest trading session, marking a +0.26% move from the prior day.

Zacks Investment Research - 7 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 8 months ago

In the latest trading session, ASLAN Pharmaceuticals Ltd (ASLN) closed at $1.65, marking a +0.61% move from the previous day.

GlobeNewsWire - 9 months ago

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

GlobeNewsWire - 9 months ago

ASLAN intends to resume screening as soon as government restrictions are lifted and is taking steps to open sites in Australia to accelerate recruitment

Zacks Investment Research - 10 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

GlobeNewsWire - 10 months ago

SINGAPORE, March 18, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...

Zacks Investment Research - 11 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.10, moving -1.87% from the previous trading session.

Zacks Investment Research - 11 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) closed at $2.11 in the latest trading session, marking a -0.94% move from the prior day.

Zacks Investment Research - 11 months ago

ASLAN Pharmaceuticals Ltd. (ASLN) closed the most recent trading day at $2.17, moving +0.93% from the previous trading session.

Zacks Investment Research - 1 year ago

Is (ASLN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 1 year ago

Is (ASLN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in ASLAN Pharmaceuticals.

GlobeNewsWire - 1 year ago

SINGAPORE, Dec. 06, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced the c...

Market Watch - 1 year ago

The U.S.-listed shares of Aslan Pharmaceuticals Ltd. plunged 47% in active afternoon trading on Tuesday, after the Singapore-based biotechnology company's stock offering priced at less than h...

24/7 Wall Street - 1 year ago

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) has been on a roller coaster for the past two weeks.

GlobeNewsWire - 1 year ago

SINGAPORE, Dec. 03, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Limited (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that ...

Market Watch - 1 year ago

Shares of Aslan Pharmaceuticals Ltd. jumped 42% on heavy volume in afternoon trading, but pared by more than half earlier gains of over 100%, after the biotechnology company took advantage of...

GlobeNewsWire - 1 year ago

SINGAPORE, Dec. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has ...

Benzinga - 1 year ago

After soaring 81.25% Wednesday and augmenting the gains by an incremental 65% Friday, ASLAN PHARMACEU/ADR (NASDAQ: ASLN) shares were  accelerating further Monday morning.

Market Watch - 1 year ago

Shares of Aslan Pharmaceuticals Ltd. soared 77% in active premarket trading Monday, after the Singapore-based biopharmaceutical company revealed positive preliminary data from a proof-of-conce...

GlobeNewsWire - 1 year ago

- ASLAN004 demonstrates early signs of efficacy in the low dose cohort of multiple ascending dose study

GlobeNewsWire - 1 year ago

SINGAPORE, Nov. 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that new prec...

Benzinga - 1 year ago

ASLAN PHARMACEU/ADR (NASDAQ: ASLN) shares are trading at sub-$1 levels following a clinical readout from the company.

GlobeNewsWire - 1 year ago

- The study did not meet its co-primary endpoints. The primary analysis of PFS yielded a hazard ratio of 0.90 in favour of varlitinib, and the ORR for varlitinib was 9.4% versus 4.8% in the co...

Zacks Investment Research - 1 year ago

ASLAN Pharmaceuticals Ltd. (ASLN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 1 year ago

- Multiple ascending dose study will assess the safety and efficacy of ASLAN004 in patients with moderate to severe atopic dermatitis

GlobeNewsWire - 1 year ago

SINGAPORE, Oct. 18, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced it has secure...

GlobeNewsWire - 1 year ago

SINGAPORE, Oct. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced  the presenta...

GlobeNewsWire - 1 year ago

- ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investing up to US$5 million 

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Industry
Biotechnology
IPO Date
May 4, 2018
CEO
Carl Firth
Stock Exchange
NASDAQ
Ticker Symbol
ASLN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for ASLN stock is "Buy." The 12-month stock price forecast is 5.50, which is an increase of 124.49% from the latest price.

Price Target
$5.50
(124.49% upside)
Analyst Consensus: Buy